Last reviewed · How we verify
Placebo to L50/H12.5 — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo to L50/H12.5 (Placebo to L50/H12.5) — Merck Sharp & Dohme LLC. This is a placebo control arm in a clinical trial comparing a fixed-dose combination of L50/H12.5 against placebo.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo to L50/H12.5 TARGET | Placebo to L50/H12.5 | Merck Sharp & Dohme LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo to L50/H12.5 CI watch — RSS
- Placebo to L50/H12.5 CI watch — Atom
- Placebo to L50/H12.5 CI watch — JSON
- Placebo to L50/H12.5 alone — RSS
Cite this brief
Drug Landscape (2026). Placebo to L50/H12.5 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-l50-h12-5. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab